KatharineAPriceMD

Oncology • Rochester, MN

Head & Neck Cancer

Associate Professor, Oncology, Mayo Medical School

Join to view full profile

Dr. Price is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Price's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2003 - 2006
Mayo Clinic College of MedicineClass of 2003

Certifications & Licensure

MN State Medical License 2004 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2

Publications & Presentations

PubMed

519 citations
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Yucai Wang, Shouhao Zhou, Fang Yang, Xinyue Qi, Xin Wang
JAMA Oncology. 2019-07-01
12 citations
Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Kyriakos Chatzopoulos, Andrea R. Collins, Sotiris Sotiriou, Michael G. Keeney, Daniel W. Visscher
Head and Neck Pathology. 2020-04-29
19 citations
Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.
Caroline Even, Jean-Pierre Delord, Katharine A Price, Kazuhiko Nakagawa, Do-Youn Oh
European Journal of Cancer. 2022-08-01

Lectures

Long-term survival of adjuvant high-dose (HDC) vs weekly cisplatin (WC) for human papilloma-virus (HPV) and non-HPV head and neck squamous cell carcinoma (HNSCC).
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Authored Content

Salivary Gland Cancer Research Got a Boost at ASCOJune 2019
Salivary Gland Cancer Research Got a Boost at ASCOJune 2019
The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 2018
The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 2018
The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 2018
The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 2018
Join now to see all

Press Mentions

The Debate Surrounding Treatment De-Escalation for HPV-Positive Oropharynx CancerFebruary 26th, 2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member